We have investigated the requirement for whole body irradiation (WBI) to achieve engraftment of syngeneic pluripotent hematopoietic stem cells (HSCs). Recipient B6 (H-2b; Ly-5.2) mice received various doses of WBI (0 to 3.0 Gy) and were reconstituted with 1.5 X 1 O7 T-cell-depleted (TCD) bone marrow cells (BMCs) from congenic Ly-5.1 donors. Using anti-Ly-5.1 and anti-Ly-5.2 monoclonal antibodies and flow cytometry, the origins of lymphoid and myeloid cells reconstituting the animals were observed over time. Chimerism was at least initially detectable in all groups. However, between 1.5 and 3 Gy WBI was the minimum irradiation dose required to permit induction of longterm (at least 30 weeks), multilineage mixed chimerism in 100% of recipient mice. In these mice, stable reconstitution with approximately 70% to 90% donor-type lymphocytes, granulocytes, and monocytes was observed. suggesting that pluripotent HSC engraftment was achieved. About 50% of animals conditioned with 1.5 Gy WBI showed evidence for donor pluripotent HSC engraftment. Although low levels of chimerism were detected in un-ONOR-SPECIFIC transplantation tolerance can be induced in irradiated animals using allogeneic bone marrow transplantation (BMT).'.* However, BMT after conditioning with lethal whole body irradiation (WBI) is associated with considerable toxicity, and would not be justified for use in patients needing solid organ transplants for the treatment of nonmalignant diseases. It would therefore be desirable to develop a nontoxic, reliable conditioning regimen permitting induction of mixed chimerism in humans after HLA-mismatched allogeneic BMT to induce specific transplantation tolerance and avoid the risks associated with chronic immunosuppressive therapy. Such a nonmyeloablative conditioning regimen has recently been developed in mice. This regimen involves the use of anti-CD4 plus anti-CD8 monoclonal antibodies (MoAbs) to specifically eliminate host immune cells that resist alloengraftment, followed by low-dose (3 Gy) WBI, 7 Gy thymic irradiation, and injection of allogeneic BMC on day 0.3 This regimen permits the induction of stable mixed chimerism and donor-specific transplantation tolerance. However, in recipients not treated with WBI, neither mixed chimerism nor allograft tolerance is achieved, even if anti-CD4 plus CD8 MoAbs are injected repeatedly or if additional MoAbs are administered4 (Y. Tomita et al, manuscript in preparation). Thus, WBI is clearly needed to achieve allogeneic engraftment in this model. However, it is not known whether a lower WBI dose would suffice and whether the requirement for WBI reflects a need to make the host environment permissive for any hematopoietic stem cell (HSC) engraftment or reflects a need for the immunosuppressive effect of WBI. Because lower WBI doses are associated with less toxicity, an understanding of the requirement for WBI is important for the design of nonmyeloablative regimens that might be used clinically to permit BM engraftment and induction of donor-specific transplantation tolerance. We have used a syngeneic BMT model to address this question. and HSCs, respectively, in the marrow of animals originally conditioned with only 0.5 Gy WBI. These results suggest that syngeneic pluripotent HSCs cannot readily engraft unless host HSCs sustain a significant level of injury, as is induced by 1.5 to 3.0 Gy WBI. We also attempted to determine the duration of the permissive period for syngeneic marrow engraftment in animals conditioned with 3 Gy WBI. Stable multilineage chimerism was uniformly established in 3-Gy-irradiated Ly-5.2 mice only when Ly-5.1 BMC were injected within 7 days of irradiation. suggesting that repair of damaged host stem cells or loss of factors stimulating engraftment may prevent syngeneic marrow engraftment after day 7 .
ONOR-SPECIFIC transplantation tolerance can be induced in irradiated animals using allogeneic bone marrow transplantation (BMT).'.* However, BMT after conditioning with lethal whole body irradiation (WBI) is associated with considerable toxicity, and would not be justified for use in patients needing solid organ transplants for the treatment of nonmalignant diseases. It would therefore be desirable to develop a nontoxic, reliable conditioning regimen permitting induction of mixed chimerism in humans after HLA-mismatched allogeneic BMT to induce specific transplantation tolerance and avoid the risks associated with chronic immunosuppressive therapy. Such a nonmyeloablative conditioning regimen has recently been developed in mice. This regimen involves the use of anti-CD4 plus anti-CD8 monoclonal antibodies (MoAbs) to specifically eliminate host immune cells that resist alloengraftment, followed by low-dose (3 Gy) WBI, 7 Gy thymic irradiation, and injection of allogeneic BMC on day 0.3 This regimen permits the induction of stable mixed chimerism and donor-specific transplantation tolerance. However, in recipients not treated with WBI, neither mixed chimerism nor allograft tolerance is achieved, even if anti-CD4 plus CD8 MoAbs are injected repeatedly or if additional MoAbs are administered4 (Y. Tomita et al, manuscript in preparation). Thus, WBI is clearly needed to achieve allogeneic engraftment in this model. However, it is not known whether a lower WBI dose would suffice and whether the requirement for WBI reflects a need to make the host environment permissive for any hematopoietic stem cell (HSC) engraftment or reflects a need for the immunosuppressive effect of WBI. Because lower WBI doses are associated with less toxicity, an understanding of the requirement for WBI is important for the design of nonmyeloablative regimens that might be used clinically to permit BM engraftment and induction of donor-specific transplantation tolerance. We have used a syngeneic BMT model to address this question. and HSCs, respectively, in the marrow of animals originally conditioned with only 0.5 Gy WBI. These results suggest that syngeneic pluripotent HSCs cannot readily engraft unless host HSCs sustain a significant level of injury, as is induced by 1.5 to 3.0 Gy WBI. We also attempted to determine the duration of the permissive period for syngeneic marrow engraftment in animals conditioned with 3 Gy WBI. Stable multilineage chimerism was uniformly established in 3-Gy-irradiated Ly-5.2 mice only when Ly-5.1 BMC were injected within 7 days of irradiation. suggesting that repair of damaged host stem cells or loss of factors stimulating engraftment may prevent syngeneic marrow engraftment after day 7 .
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If WBI is needed only for its immunosuppressive effect in the allogeneic model, then it should not be required to achieve engraftment in a syngeneic combination. If, on the other hand, WBI is needed to create a permissive environment for HSC engraftment, then it would also be required in a syngeneic combination. We used the Ly-5 congenic strain combination involving B6.Ly-5.2 (Ly-5. l ) donors and C57BL/6 (B6; L~-5 . 2 )~ recipients, and examined engraftment in recipients pretreated with 0, 0.5, 1.5, or 3 Gy WBI. Because Ly-5 is a leukocyte common antigen expressed on all hematopoietic lineages, this system allowed us to observe the origin (donor versus host) of myeloid and lymphoid cells over time and to thus evaluate pluripotent HSC engraftment. Ly-5 alleles have been shown not to elicit alloresistance or graft rejection,6 so engraftment could be evaluated in the absence of alloreactivity. The results indicate that between 1.5 and 3 Gy is the minimum WBI dose required to permit pluripotent HSCs contained in clinically attainable marrow doses to engraft in 100% of syngeneic recipients.
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MATERIALS AND METHODS
ilnima/s. Female C57BL/6NCR (B6; H-2b, L~-5 . 2 )~ and female Ly-5 congenic B6.Ly-5.2 (Ly-5.1) mice were obtained from the Frederick Cancer Research Facility (Frederick, MD). Ly-5 alleles are described according to the nomenclature of Morse et aL5 All mice were housed in sterilized microisolator cages in which they received autoclaved food and autoclaved acidified drinking water. Recipients were age-matched and were used at 12 to 16 weeks of age.
BMT. BMT was performed as previously described.' Briefly, recipient B6 mice were irradiated with various doses (0.5 to 9.5 Gy; "' CS source, approximately 1 .O Gy/min) and reconstituted with Tcell-depleted (TCD) Ly-5. I BM cells (BMCs I .5 X lo7 unless indicated otherwise) obtained from the tibiae and femora of sexmatched B6.Ly-5.2 donors aged 6 to 14 weeks. TCD was performed as described' using anti-CD4' and CD89 MoAbs and C.
Cc// counts. Heparinized peripheral blood was analyzed on an Automated Cell Counter (System 9000; Serono-Baker Diagnostics Inc, Allentown, PA).
Phmutyping of'chimerus. Phenotyping was performed at various times beginning 2 weeks after BMT. Animals were tail bled and white blood cells (WBCs) were prepared by hypotonic shock. Suspensions of spleen cells, thymocytes, BMCs, and BM colonies were also analyzed. Staining with both donor-specific and recipient-specific MoAb was performed on each chimera and control animal. Cells were incubated with 20 pL undiluted culture supernatant of A20-I .7 (anti-Ly-5. I MoAb; mouse IgG2a) or 104-2. I (anti-Ly-5.2 MoAb; mouse IgC2a)5 (hybridomas kindly provided by Dr S. Kimura, Sloan Kettering Cancer Institute. New York, NY) for 30 minutes at 4°C and then washed twice. To block nonspecific FcyR binding of labeled antibodies, 10 pL undiluted culture supernatant of 2.462 (rat antimouse FcyR MoAb)" was added to the first incubation. Cell-bound MoAbs were detected with fluorescein isothiothianate (F1TC)-conjugated rat antimouse IgC2a MoAb (Zymed Laboratories, Inc, Mundelein, IL), which wasincubated for 30 minutes at 4"C, followed by two washes and analysis on an FACScan (Becton Dickinson, Mountain View, CA). In all experiments, the percentage of cells staining with each MoAb was determined from one-color fluorescence histograms and comparison with those obtained from normal donor and host-type animals, which were used as positive and negative controls. The percentage ofcells considered positive after staining with an MoAb was determined using a cutoff chosen as the fluorescence level at the beginning ofthe positive peak for the positive control strain, and by subtracting the percentage of cells stained with an irrelevant MoAb (nonreactive lgG2a MoAb HOPCI plus FITC-conjugated antimouse IgG2a MoAb). The relative percent staining of a chimera with MoAb was calculated using the formula: 100% X (net chimera percent positive) -(net negative control percent positive)/(net positive control percent positive) -(net negative control percent positive), in which "net" percent positive refers to the percentage obtained after subtraction of staining with HOPCI, and positive and negative controls were cells from appropriate normal Ly-5.1' and Ly-5.2' mice. For test cell populations in which staining with an anti-Ly-5 MoAb was less than that of the negative control and the calculated percent chimerism was therefore less than 0, the values are reported as 0. Using this method of calculation, less than 0. I% contaminating Ly-S. I + cells could be detected in artificial Ly-5.2 (99.9%)/Ly-5. I (0.1%) mixtures. However, a visible positive peak was not detectable in artificial mixtures containing 0. I% or fewer Ly-5.1' cells, but was visible with I% contaminating Ly-5.1' cells (data not shown). All hematopoietic lineages stained strongly with anti-Ly-5 MoAb." By using forward and 90" light scatter (FSC and SSC, respectively) dot plots, lymphocyte (FSC-and SSC-low population), granulocyte (SSC-high population), and monocyte (FSC-high but SSC-low population) populations were gated, and chimerism was determined separately for each population. All SSC-high cells in the granulocyte gate stained with FITC-conjugated antimouse granulocyte MoAb (Gr-l) (data not shown). Dead cells were excluded by gating out low FSC/high propidium iodide-retaining cells.
Colony-forming unit (CFW) assay. Thirty-three thousand BMCs were cultured in I mL of Iscove's 2.3% methylcellulose (HCC-410; Terry Fox Laboratory, British Columbia, Canada) medium, supplemented with 5% mouse interleukin-3 (IL-3)"containing supernatant (WEHI-3 supernatant, Lot No. 906852; Becton Dickinson, Bedford, MA), 30% fetal calf serum (FCS; Hyclone, Logan, UT), 5 X IO-' mol/L 2-ME, 15% Iscove's modified Dulbecco's medium (Mediatech, Washington, DC), and antibiotics (50 U/mL penicillin and 50 pg/mL streptomycin) in a culture flask (Cat. No. I7 1099: Nunc, Inc, Naperville. IL). Eight days later, colonies were enumerated and were then harvested and stained for phenotyping by flow cytometry (FCM), as described above.
Statisrics. Statistical analysis was performed using Student's 1-test. A P value of less than .05 was considered to be statistically significant. B6 mice rmmstitrtted with 1.5 X IO7 Ly-5.1 BMCs. To assess the degree of myelosuppression induced by various doses of WBI, WBC and platelet counts and hemoglobin concentrations were measured at various times after irradiation and BMT. As shown in Fig 1 a , decreased WBC counts were only transiently observed in recipients treated with l .5 or 3.0 Gy WBI, and the degree of reduction was proportional to the WBI dose administered. Hemoglobin concentrations decreased to an average of 10.6 g/dL by day 4 and then gradually recovered to normal levels by day 29 in 3-Gy-irradiated B6 mice receiving Ly-5.1 BMCs. No change in hemoglobin concentration was observed in the other groups. Platelet numbers showed an increase above normal at day 4 that was more marked with increasing irradiation doses and decreased to normal levels by day 7 (Fig 1) .
RESULTS
Kinetics of hematopoietic recovery in irradiated
Three Gray WBI is required .for establishment of' stable multilineage hemopoietic chimerism. To examine the kinetics of mixed chimerism in B6 (Ly-5.2') mice irradiated and reconstituted with congenic Ly-5.1' BMCs, FCM analysis was performed. In WBCs of unirradiated B6 recipients (n = 4) injected with congenic Ly-5. I BMCs, a low percentage of Ly-5.1+ cells (54%) was detected at 2 and 6 weeks after BMT, but Ly-5.1' cells were no longer detectable by 20 weeks after BMT. Similar levels of chimerism were observed for lymphocytes, granulocytes, and monocytes (Table l).
Similar results were obtained in B6 mice (n = 5) injected with Ly-5. I BMCs after irradiation with 0.5 Gy WBI ( Table  1) . Although initial chimerism was slightly geater than that observed in unirradiated recipients, Ly-5.1' cells became undetectable by 20 weeks after BMT.
As shown in Fig 2 and summarized in Table 1 , a different result was obtained in B6 mice irradiated with 1.5 Gy and injected with Ly-5. I BMCs. In 2 of 5 recipients, Ly-5.1' cells increased to 54% and 66% of WBCs by 12 weeks after WBI and remained constant for the entire follow-up period of 30 weeks. Similar levels of Ly-5. I reconstitution were observed for lymphocytes, granulocytes, and monocytes of each ani- mal. However, in the remaining 3 mice, Ly-5.1+ WBCs did not increase between 2 and 6 weeks post-BMT and began to decrease at 12 weeks post-BMT. By 30 weeks, donor cells were undetectable in one of these three mice. Although Ly-5.1+ lymphocytes remained detectable in all three mice for at least 20 weeks, granulocyte chimerism was no longer detectable by 6 weeks after BMT. In contrast to these results, stable and high levels of donor reconstitution were observed in all of 5 B6 mice receiving Ly-5.1 BMCs after irradiation with 3 Cy WBI (Fig 3 and Table I ). Donor reconstitution of all lineages increased between 2 and 12 weeks post-BMT and remained constant thereafter.
Engraftment in recipients of all irradiation doses is summarized in Table 1 For
or BM progenitors of any of 6 B6 mice injected with Ly-5.1 BMCs with or without 0.5 Cy WBI (marrow from 4 unirradiated and 2 0.5-Cy-irradiated recipients was assessed data not shown).
In the group of Ly-5.2 mice receiving l .5 G y WBI and Ly-5.1 BMCs, variable results were obtained (Fig 4a) , as had been observed for WBCs (Fig 2) .
High levels of donor repopulation were observed for all cell populations of Ly-5.2 mice irradiated with 3 C y and injected with Ly-5. I BMCs (Fig 4b) . Table 2 ), but ranged from 0% to 28% (SD, 9.2) in recipients of smaller numbers ( IO5) of the same cell mixture (group 1, Table 2 ).
As shown for groups 3 through 6 in Table 2 
least 7 days after treutment with 3 Gy WBI.
We investigated the relationship between timing of 3 C y WBI and the ability of Ly-5.1' BMCs to engraft in Ly-5.2 recipients. Irradiated Ly-5.2 mice received Ly-5.1 BMCs at various intervals from 0 to 21 days after irradiation ( Table 3) . In all animals irradiated on day 0 and receiving Ly-5.1 BMCs on day 0,4, or 7, high levels of multilineage donor-type repopulation were observed and remained stable for at least 20 weeks ( Table 3 , groups 1 through 3). In contrast, mixed chimerism was induced in only 3 of 4 and 2 of 4 recipients of Ly-5.1 BMCs on day 14 and 21, respectively ( Table 3 , groups 4 and 5). In B6 mice in which Ly-5. I + cells were initially detected only in the lymphoid but not in the granulocyte lineage, chimerism disappeared completely by 20 weeks after WBI.
DISCUSSION
A relatively nontoxic conditioning regimen allowing allogeneic BM engraftment and donor-specific tolerance induction across complete major histocompatibility complex (MHC) barriers has recently been described in mice. 3 The regimen includes administration of anti-CD4 plus anti-CD8 MoAbs on day -5 or -6, 3 C y WBI on day 0, and 7 Gy thymic irradiation on day 0, followed by injection of allogeneic BMCs on day 0. Because lower doses of WBI are associated with less toxicity, it was important to determine whether a lower WBI dose would permit stable marrow engraftment. Before embarking on such studies in an allogeneic model, we wished to determine the threshold WBI dose required to make the host environment permissive for engraftment of syngeneic marrow. To assess pluripotent HSC engraftment, we evaluated long-term (up to 8 months), multilineage reconstitution in animals conditioned with various doses of WBI. The results presented here demonstrate that between I .5 and 3.0 Cy WBI is needed to permit syngeneic pluripotent HSC engraftment in 100% of mice receiving approximately 6 X I O8 BMCs/kg.
In animals in which pluripotent HSC engraftment was not achieved, granulocyte chimerism was lost before chimerism disappeared in other lineages. Some animals in which transient granulocyte chimerism persisted for 6 weeks or less also showed lymphocyte chimerism that persisted for up to 20 weeks. However, lymphoid chimerism eventually disappeared in these mice (Table 1) . On the other hand, mixed chimerism was stably maintained in recipients in which myeloid chimerism persisted for 12 or more weeks, as was observed for some 1.5-Gy-irradiated recipients of Ly-5.1 BMCs (Fig 2) , and BMC chimerism correlated well with long-term granulocyte chimerism (Fig 4) . These results can be explained by the differing life spans and proliferative capacity of mature lymphocytes and granulocytes. In all recipients, even those not receiving WBI, donorderived Ly-5.1+ cells were detected at 2 weeks after BMT and persisted for 6 to 12 weeks, probably reflecting engraftment of short-term repopulating cells. Because some lymphocytes are very long-lived12 and can proliferate upon encounter with antigen, some lymphocytes may have survived long after hematopoiesis by injected Ly-5.1f cells had ceased. On the other hand, granulocytes do not proliferate and have a short life span, so this lineage would be expected to disappear first in the absence of donor pluripotent HSC engraftment.
Hematopoietic reconstitution has been divided into short-term and long-term phases.I3 Recent studies suggest that a progenitor cell population exists that is capable of sustaining short-term (up to 6 to 12 weeks) repopulation of multiple lymphoid and myeloid hematopoietic lineages in lethally irradiated mice.I4 Our data indicate that lower irradiation doses are required to allow repopulation by shortterm progenitors than by long-term repopulating cells of the donor, because recipients of no irradiation or of 0.5 Gy showed donor repopulation of only short-term progenitors. However, in recipients of higher irradiation doses, in which long-term donor repopulation was observed, the level of host-type reconstitution was higher in the first 2 to 6 weeks after BMT than at later time points. Thus, a lower dose of irradiation is required to achieve engraftment of short-term progenitors than of long-term repopulating HSCs, but if the latter cells engraft, they repopulate at higher levels than did short-term progenitors in the same donor inoculum. This paradox suggests that the unirradiated host environment is more permissive for engraftment of short-term progenitors than of long-term repopulating HSCs, but that recipient pluripotent HSCs may be more radiosensitive than shortterm progenitors.
It has been previously accepted that myelosuppressive treatment is needed to create the poorly defined entity known as "space" needed for HSC engraftment." However, more recently, two groups described successful hematopoietic engraftment in unconditioned recipients. Wu and Keating"j demonstrated that donorderived cells can be detected in marrow and myeloid colonies and at high frequency in day-l2 CFU-S of untreated BALB/c female mice injected with 2 X lo7 BALB/c male BMCs 8 weeks earlier. However, donor-derived cells were undetectable in peripheral blood, thymi, or spleens of these animals. Although CFU-S are probably early progenitor cells, these short-term studies do not address the possibility that pluripotent HSC engraftment was achieved, and therefore cannot be considered to conflict with our results.
In another study, Hollands" demonstrated that embryonic stem cells could reconstitute 1% to 10% of red blood cells and marrow of unconditioned recipients observed for up to 9 weeks. However, long-term follow-up of multiple hematopoietic lineages was not reported, so these results cannot be considered to demonstrate pluripotent HSC engraftment in unconditioned recipients. Notably, skin graft tolerance to hematopoietic cell donors was not observed in recipients of allogeneic embryonic cells.
Stewart et all8 reported that injected male donor cells could be detected by Southern analysis 12 months after BMT in unconditioned female BALB/c mice, with 23% to 78%, 30% to 45%, and 26% to 37% donor cells detected in
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BM, spleen, and thymus, respectively. These mice had received 5 consecutive daily injections with 4 X lo7 BALB/c male BMCs. This appears to conflict with results of our study, which provides strong evidence that pluripotent Ly-5.1' stem cells did not engraft in untreated or 0.5-Gy-irradiated Ly-5 congenic recipients (Table 1 and Fig 4) . Results of BM progenitor assays (Fig 4) and of adoptive transfer studies into lethally irradiated secondary host-type recipients (Table 2 ) confirmed the absence of Ly-5. l progenitor cells and stem cells in the marrow of these mice. Adoptive transfer assays are sensitive to the presence of minority stem cell populations when limiting numbers ofHSCs are admini~tered.'~*'~*~' Our results using mixtures of 95% Ly-5.2' BMCs and 5% Ly-5.1' BMCs confirmed that there is greater variability in the composition of repopulating cells when lower stem cell numbers are administered, because much greater variance in the percentage of donor cells was observed when lo5 BMCs were administered than was observed with lo6 BMCs (groups 1 and 2, Table 2 ). Thus, if small numbers of Ly-5.1 HSCs persisted in a quiescent state 43 weeks after transfer to 0.5-Gy-irradiated Ly-5.2 recipients, these Ly-5.1 cells might have partially reconstituted some secondary Ly-5.2 recipients of lo5 BMCs to a detectable level. This was not observed in any of 20 recipients of this cell dose, suggesting that small numbers of Ly-5.1 HSCs did not persist in a quiescent state in marrow of 0.5-Gyirradiated Ly-5.2 recipients of Ly-5.1 BMCs.
The FCM analysis technique used for detection of Ly-5.1' cells is sensitive to the presence of less than 0.1% contaminating cells in artificial cell mixtures. Although it is possible that the use of more sensitive techniques, such as the polymerase chain reaction (PCR) methodology used by Wu and Keating,16 might detect evidence for donor HSCs at a frequency below this level, such percentages would be much lower than those detected in any of the three studies referred to above. '"18 The discrepancy between our results and the results in these earlier reports may be explained by several differences in the studies. As discussed above, two of the studies do not evaluate pluripotent HSC engraftment, and therefore may not conflict with our result, in which evidence for engraftment of short-term progenitor cells was also obtained in unconditioned recipients. In addition, the long-term study of Stewart et a l l 8 was performed after administration of a 13-fold greater dose of BMCs than we administered. Brecher et a12' demonstrated that the proportion of donor cells reconstituting an unconditioned animal increased in linear proportion to the number of donor BMCs administered in the range of 2 X IO7 to 2 X lo8 BMCs. Stewart et all8 suggested that inocula of 2 X lo8 BMCs, which contains approximately two-thirds of the total number of stem cells in a normal mouse, compete effectively with host marrow by either displacing host stem cells or by entering unoccupied niches in the host marrow. Although we injected a p proximately one-twentieth of the number of stem cells contained in a normal mouse, we observed levels of donor engraftment that were well below 5%, suggesting that injected cells did not compete equally with recipient HSCs in unirradiated hosts. Although pluripotent HSC engraftment may be achieved when sufficient stem cell numbers are administered to unconditioned recipients, it is unlikely that such high numbers of BMCs (on a per kilogram basis) could be practically obtained from a living allogeneic human donor. The number of BMCs we administered (approximately 6 X 108/kg), on the other hand, is similar to that usually administered to human allogeneic BMT recipients.
Combined with the results of Stewart et aI,'* our data suggest that a major role of myelosuppressive treatment may be to damage and reduce numbers of host HSCs, thus providing a competitive advantage for injected
HSCs that are much smaller in number than those in untreated recipients. The requirement for injury of host cells to confer this competitive advantage to the donor may account for what has been referred to as the requirement to make "space" to achieve pluripotent HSC engraftment. "Space" can apparently also be created by treatment with MoAb against MHC class I antigens, 22 Another difference between the present study and those reporting achievement of engraftment without myelosuppressive host conditioning concerns the strain combinations evaluated in each study. The Ly-5 alleles used for distinguishing donor and host cells in the present study have been shown not to elicit alloresistance or graft rejection, and T cells do not affect levels of mixed chimerism in this strain combination: BMC T cells were depleted in our study, but not in the other studies referred to, which involved male to female BMC transfer in BALB/c T cells can promote allogeneic marrow engraftment, even when they genetically lack the capacity to recognize alloantigens on the re~ipient.'~.~~ This effect may be caused by veto activity, which could be mediated by H-Y antigen-expressing donor T lymphocytes that are attacked by recipient H-Y-specific cytotoxic T-lymphocytes?' or could be caused by cytokine production by host T cells reacting against donor H-Y antigens.
Our results suggest that administration of allogeneic BMCs to mice not receiving myelosuppressive therapy is unlikely to be a practical method of inducing donor-specific transplantation tolerance. Both the study of Holland17 and our own results3 ( Y . Tomita, manuscript in preparation) indicate that skin allograft tolerance to fully MHC-mismatched donors cannot be induced by hematopoietic cell transfer to unirradiated recipients, even when host T cells are depleted. In our sublethal irradiation/TCD/BMT For personal use only. on October 30, 2017 . by guest www.bloodjournal.org From model, we have shown that persistent chimerism is necessary to maintain permanent tolerance," probably because T cells develop in the host thymus in the absence of donor antigen after chimerism has been intentionally eliminated (Y. Tomita, V.S. Abraham, D.H. Sachs, M. Sykes, manuscript in preparation).
In 3-Gy-irradiated B6 recipients of Ly-5.1 BMCs on day 0 (ie, the day of irradiation), 4, or 7, a high level of multilineage donorderived hematopoiesis was achieved and maintained long-term in all mice (Fig 3 and Table 2 ), indicating that "space" for pluripotent HSC engraftment persists for at least 1 week after 3 Gy WBI in all animals. In 5 of 8 animals, HSC engraftment was still achieved when BMCs were administered as late as 21 days after irradiation ( Table 3) . A decline in WBC counts was observed in 3-Gy-irradiated mice 2 to 7 days after irradiation, but these counts recovered to normal by day 14 (shown in Fig 1A for recipients of Ly-5.1 BMCs; similar results were observed in 3-Gy-irradiated mice not receiving BMC injections [L.A. Lee and M. Sykes, unpublished data]). In recipients of 1.5 Gy WBI with or without BMT, a reduction in WBC counts was also observed in this period (Fig l A) , whereas no significant decline was observed in recipients of lower irradiation doses. Thus, our data indicated that reductions of WBC counts may serve as a crude marker for the presence of a host environment that permits HSC engraftment, but do not correlate perfectly, because WBC counts recover to normal at a time when the environment is still permissive in many animals.
It would be desirable to develop a nontoxic, reliable conditioning regimen permitting induction of mixed chimerism in humans after HLA-mismatched allogeneic BMT, to induce specific transplantation tolerance and avoid the risks associated with chronic immunosuppressive therapy. Achievement of this goal would also have applicability to a variety of nonmalignant hematologic diseases. The present studies show that a mild myelosuppressive treatment must be included in any such regimen, even in the absence of immune-mediated alloresistance, which, at least in the mouse, can be overcome using specific MoAbs.' We have recently demonstrated that the requirement for 7 Gy thymic irradiation in our nonrnyeloablative conditioning regimen for murine allogeneic BMT can be avoided by administering additional TCD antibodies, making the regimen even less potentially toxic (Y. Tomita, D.H. Sachs, and M. Sykes, manuscript in preparation). Studies are in progress to extend these results to a primate model.
